BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
March 22, 2005
View Archived Issues
Onyx, Bayer Plan To File NDA For Sorafenib On Interim Data
Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. plan to file for FDA approval of BAY 43-9006, which has been renamed sorafenib, based on interim Phase IIII data from a study in advanced kidney cancer patients. (BioWorld Today)
Read More
Sequoia Raises $22M To Fund Programs In Viral Infections
Read More
Avastin Competitor Misses Endpoint; Genentech Jumps
Read More
Biolex Signs Up Centocor In Wide-Ranging Protein Deal
Read More
Other News To Note
Read More
U.S. Patent Disclosures
Read More